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Introduction
Lung cancer is the leading cause of cancer deaths for
people of both sexes worldwide [8,24,61]. This high
mortality rate is first of all due to the fact that most
cases of lung cancer are diagnosed at an advanced
stage of development. An expanded diagnostics of
preinvasive conditions, which are referred to as pre-
cancer lesions, would certainly contribute to lowering
the mortality rate. It is, however, a big challenge, con-
sidering that the whole lung is a potential area of can-
ceration, and neoplasia has many different potential
ways of development [41].
Lung cancer develops in two separate compart-
ments - the central (transporting air) and the peripher-
al (respiratory) part of the lung. There are four histo-
logical types of cancer, including small cell cancer and
a heterogeneous group of non-small cell cancer, which
includes squamous cell carcinoma, adenocarcinoma
(including a non-invasive type of bronchoaveolar car-
cinoma), large cell cancer and many other, much less
frequent subtypes. 
A long term exposure of the epithelium lining the
airways to different carcinogens, including most of all
cigarette smoke, causes a number of mutations of the
cells placed in different compartments.  These multi-
phase changes with a diversified morphology result in
the development of a fully invasive type of cancer
[14,47]. Thus, lung cancer may develop both in the pri-
mary bronchus, small bronchioli  and alveoli. Squa-
mous cell carcinoma is most often placed centrally
whereas adenocarcinoma and large cell cancer are typ-
ically encountered in the peripheral part of the lung
(Fig. 1 and 2).  
Morphology of pre-cancer lesions
The recently published WHO classification of lung
tumours identifies three main pre-cancer states leading
to the development of invasive types of cancer. These
are: squamous dysplasia and carcinoma in situ (CIS),
atypical adenomatous hyperplasia (AAH) and diffuse
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idiopathic pulmonary neuroendocrine cell hyperplasia
(DIPNECH) [9]. 
Progressive morphological changes of the epitheli-
um, which in most cases lead to the development of an
invasive type of squamous carcinoma, have been
examined and described quite well [10,65]. These
changes progress from epithelial cell hyperplasia,
through squamous metaplasia and the accompanying
dysplasia, to carcinoma in situ (Fig. 1). Hyperplasia
may affect two types of cells: goblet and basal. The
lesion is referred to as basal cell proliferation when the
base layer of epithelium is thickened and it is more
than 3 cell thick [14]. Metaplastic lesions occur main-
ly in the place where there is already a proliferation of
basal cells. These cells, as a result of the differentiation
process, create layers characteristic for stratified squa-
mous epithelium. Squamous dysplasia, which is con-
sidered to be a real pre-cancer lesion, may differ in the
stage of development (low, mild and high grade). Low-
grade dysplasia is a lesion characterised by minimal
aberration inside the cell. Only single atypical cells
appear in the epithelium. The stratified structure of the
epithelium is retained. A bigger irregularity is
observed in the case of mild and high-grade dysplasia.
In the latter there is a significant polymorphism affect-
ing all the cells. Still, the stratified structure of the
epithelium can be seen. In some cases of metaplasia or
squamous dysplasia, we can observe significant thick-
ening of the basal layer, while under the epithelium the
vascularization process starts, which results in the for-
mation of papillary processes. This lesion has been
described as angiogenic metaplasia/squamous dyspla-
sia [28]. Carcinoma in situ may be accompanied by
thickening of the epithelium although it is not always
the case.  Epithelium is not stratified and the cells are
not fully mature. We can observe a severe derange-
ment of the cytology of the cells, such as the change of
nucleus shape and size, a deranged relation between
the nucleus and the cytoplasm and nuclear hiperchro-
masia.  Cell division figures are observed on all levels
[14,30].
The lesions affecting the respiratory part of the
lung, which most often lead to the development of
adenocarcinoma, are connected with 2 morphological-
ly separate states. 
Atypical adenomatous hyperplasia (AAH) is observed
as solitary or multifocal lesions within a normal lung as
well as lesions creating a continuity with a tumour con-
sisting of adenomatous tissue. This lesion was first
described in 1939 as proliferating, non-inflammatory
lesion of the alveolar epithelium [19]. AAH is a small,
proliferating lesion, whose size varies from 1mm to
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Fig. 1. Multistep progression to invasive squamous carcinoma.
Fig. 2. Multistep progression to invasive adenocarcinoma.
about 7 mm, usually it is less than 3 mm. It  most often
occurs in the peripheral part of the lung and takes the
form of a single layer of atypical cells similar to Clara
cells or type II pneumocysts, covering  alveoli and res-
piratory bronchioli. AAH cells are cuboidal or colum-
nar. They show a different degree of cell atypia. Mitot-
ic division figures are rarely visible in AAH. Intercel-
lular connections are in most cases retained, with few
occasional empty spaces between the cells. Contrary to
the reactive proliferation of type II pneumocysts (bron-
chiolisation), in the proximity of atypical cells there
are no, or they are very weakly manifested, features of
interstitial inflammation and fibrosis. Some authors
notice that AAH cells are at least twice as big as the
neighbouring normotypical alveolar epithelium. These
cells form a single layer consisting of round and/or
cuboidal cells of low concentration. The nuclei of
these cells show minimal features of atypia (changes in
the size and shape as well as hiperchromasia).  As
AAH progresses, we can observe a slight thickening of
alveolar septa, an increase in the concentration of cells
and their overlaying with the formation of papillae.
There is also the stratification of epithelial cells and a
strongly manifested cell atypia. Despite a clear mor-
phological diversification of these states, in practice
AAH is not classified into low, mild and high grade
[43,46,52,60].
Many authors put forward hypotheses that AAH
leads both to the development of a non-invasive type
of bronchioloalveolar carcinoma (BAC) and the inva-
sive adenocarcinoma (AC)(Fig. 2). The frequency of
AAH in the population is unknown. Nakahara et al.
[44], examined 508 patients operated for primary lung
cancer and found 118 (23.2%) patients with diagnosed
311 AAH lesions in total. On the other hand, the
research conducted by Chapman and Kerr [11] cover-
ing 582 patients operated for primary lung cancer,
points to 67 (12%) patients with diagnosed AAH. 
Atypical adenomatous hyperplasia is more often
observed in patients operated for adenocarcinoma
(even up to 40% of cases) than in patients suffering
from squamous carcinoma  (about 9%) [30,31,33,46,
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Fig. 3. Probable multistep progression to invasive adenocarcinoma.
55,57,64]. Weng et al. [64] claim that the occurrence
of AAH is irrelevant to sex whereas Chapman and
Kerr [11] point to a more frequent AAH incidence in
women operated for adenocarcinoma (30.2%) than in
men (18.8%) operated for the same reason. Further
research involving post-mortem examinations indi-
cates incidental (2-3%) occurrence of AAH in patients
who had not been diagnosed with primary or second-
ary carcinoma [56,68].
In 2003 Ullman and Bongiovanni [62] described a
new, so far unobserved lesion, which they called
"Bronchiolar Columnar Cell Dysplasia" (BCCD).
Unlike AAH, which can be observed by means of
macroscopic methods, BCCD requires the application
of microscopic methods. 
BCCD is characterised by the derangement in the
organization of the epithelial layer of bronchioli. Nor-
motypical columnar cells, as well as reserve cells are
replaced with a uniform continuum of atypical colum-
nar, cubic or polygonal cells, which may form multiple
layers. From the cytological point of view, the atypia
of these cells is manifested by the lack of diagonal ori-
entation of the nucleus, its enlargement and the appear-
ance of the nucleolus, hiperchromasia.  We also
observe derangements in nucleus shape and chromatin
condensation.  Multinuclear cells are also frequent.
The authors of the quoted study believe that the
hypothesis that BCCD lesions may precede the devel-
opment of adenocarcinoma, is confirmed by the occur-
rence of lesions in the peripheral part of the lung, a
similarity between BCCD and the lesions preceding
the development of adenocarcinoma, which occur in
other organs (prostate and pancreas) and have already
been described well. An important argument are the
results of LOH (the loss of heterozygosity) tests,
which are performed on the BCCD epithelium [62].
They may indicate the way of development from
BCCD to adenocarcinoma (Fig. 3).
Another lesion observed in the respiratory part of
the lung, which may have a potential connection with
cancerogenesis, is a reactive proliferation of type II
pneumocysts, known as bronchiolisation (Fig. 3).  
Bronchiolisation is most often observed as a focal
lesion occurring within a normal respiratory epitheli-
um. This lesion can be described as a metaplasia of this
epithelium in the direction of type II respiratory
epithelium cells or columnar cells of bronchioli.  As
the lesion develops, we can observe a diversity of sizes
and shapes of cells. In our material (the lungs resected
due to primary cancer) we came across the cases of
bronchiolisation with the presence of atypical cells.
The process of bronchiolisation is usually accompa-
nied by focal lesions of interstitial fibrosis. In bronchi-
olisation foci the epithelium often forms micro-papil-
lae. Lesions of this type have been observed both in
connection with squamous carcinoma, adenocarcino-
ma and the mixed type, as well as in other pathologi-
cal processes involving lung fibrosis [25].
Immunohistochemical markers in pre-cancer
lesions 
The current hypothesis referring to cancerogenesis
suggests that the observed phenotype of the cells
suspected to be responsible for the malignancy
process is the consequence of lesions occurring in
the genes taking part in the regulation of the cell
cycle, cell proliferation and division, DNA repair,
the transmission of growth signals and apoptosis
[54]. Changes in the expression of genes as well as
in the chromosome structure, which lead to cancer-
ous transformation, are observed in the case of squa-
mous metaplasia, dysplasia, CIS, as well as AAH or
bronchiolisation. These changes occur in sequences
and their number and frequency increases together
with the development of atypia along both pathways
of development; metaplasia - dysplasia - CIS and
AAH - adenocarcinoma [20].
Bcl-2
Bcl-2 protein has anti-apoptotic qualities. Its over-
expression provides the differentiating cancer cells
with an unlimited freedom of development. It is
observed in 25% of squamous carcinoma cases and
about 10% of mature adenocarcinoma [7,29,50,63]. In
the states preceding the development of an invasive
type of squamous carcinoma, the over-expression of
bcl-2 is slightly connected with the growing atypia. It
occurs with the same frequency and intensity in the
lesions such as low and high-grade dysplasia and CIS,
with the exception of squamous metaplasia, where the
over-expression of this protein is lower. Bcl-2 over-
expression in metaplastic cells and those showing the
features of low-grade dysplasia, is closely related to
tumour proximity.  Mild and high-grade dysplasia and
CIS do not show such a tendency [5]. Bcl-2 over-
expression in atypical adenomatous hyperplasia cells
is significant and reaches about 70% [27]. Bcl-2 over-
expression is related to the inactivation of pro-apoptot-
ic bax protein. Bax/bcl-2 relation (BBR), which in nor-
motypical epithelial cells is >1, is significantly oppo-
site in pre-cancer lesions, starting from mild dysplasia,
i.e. <1 [36].
Survivin
Survivin, which is another anti-apoptotic protein, does
not occur in normotypical epithelial cells and low-
grade AAH. Its expression is observed in 25% of squa-
mous metaplasia cases, 40% of low-grade dysplasia
cases and 61% of high-grade dysplasia cases, which
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indicates an upward tendency in every stage of squa-
mous carcinoma. The expression of survivin is
stronger manifested in pre-cancer lesions situated in
the immediate proximity of the tumour. It also applies
to the cases of AAH which adhere to bronchioloalveo-
lar carcinoma (BAC) [2].
p53
The expression of p53 protein is connected with the
cell DNA damage.  This protein stops the cell cycle
by initiating the expression of p21 protein (the imme-
diate inhibitor of cdk2), and at the same time triggers
cell reconstruction systems. In the case of a bigger
damage, it puts the cell on the pathway to apoptosis
[18]. Point mutations, affecting most often the 5-8
exon of p53 gene, result in the formation of abnormal
protein, which is not able to regulate transcription
correctly. The formed protein, even though it is func-
tionally abnormal, is very stable and accumulates in
cells [18,37]. Derangements of p53 protein expres-
sion are the most often observed lesions in the inva-
sive types of lung cancer [21] and seem to be playing
a vital role in the multi-degree pathway of cancerous
lesion development [14]. The expression (accumula-
tion) of mutated p53 protein occurs already in early
stages of invasive cancer development (Fig. 5).  Dif-
ferent studies point to an upward tendency in p53
protein accumulation in the states preceding the
development of squamous carcinoma. This accumu-
lation ranges from 5% in squamous metaplasia cases
to about 60% in an advanced high-grade dysplasia
[3,6,13,22]. Brambilla et al. [5] reports a positive
reaction to p53 in all examined cases of a pre-cancer
nature (dysplasias, CIS). Just like in the case of bcl-
2, the distance between the lesion and the tumour was
an important factor, which influenced the frequency
of positive reactions. In the material obtained from
'non-cancer' patients there was no p53 accumulation
in the lesions considered as pre-cancer. The conclu-
sion that can be drawn from that is that p53 over-
expression in pre-cancer states has a significant
influence on the development of a non-invasive
lesion. Kerr et al. report  28% accumulation of p53
protein in atypical adenomatous hyperplasia [31]. In
the same study, a positive expression in the tumour
was observed in 53% cases. The research conducted
by  Kitamura et al. [32] indicates p53 expression in
5-8% of AAH cases and 8-62% of bronchioloalveolar
carcinoma (BAC) cases. Martin et al. [38] reports
that abnormal expression of p53 protein in single
cells happens in 28% cases of normotypical epitheli-
um of smokers. It has an upward tendency increasing
together with the development of the lesion and
affects 71% of cases already on the level of low-
grade dysplasia. What is interesting is that in carci-
noma in situ and invasive carcinoma, the positive
reaction to p53 is encountered in 64% of cases (posi-
tive colour reaction in more than 10% of cells). Only
in 2 out of 32 cases of bronchiolisation there was a
strong, but focal, p53 expression [25]. It must be
taken into account that the immunohistochemical
method is able to define over-expression only in the
case of protein p53. Only the methods of molecular
biology are able to define mutation in exons, which
do not lead to the accumulation of protein in the cell
and, therefore, are not detectable by means of  the
immunohistochemical method [4]. 
Telomerase
Telomerase is another factor which contributes to cell
immortality.  It may lead to blocking the normal short-
ening of telomeres, which protects the cells against the
regular aging process. The expression of hTERT
(human telomerase reverse transcriptase) has a clear
upward tendency, starting from hyperplasia, where the
expression is weakly manifested and occurs in about
70% of cases and squamous metaplasia (88%) and fin-
ishing with different grades of dysplasia (96-100%)
and CIS (100%), where there is a strong manifestation
of expression.  The level of the expression of this
enzyme depends significantly on lesion advancement,
which has also been proved by the researchers by
means of in situ hybridisation for hTERT mRNA.
Authors also point to a correlation between hTERT
expression and p53 accumulation as well as a reverse
BBR. On the other hand, no significant relations
between telomerase activation, D1 cyclin over-expres-
sion and the loss of p16 expression, have been noticed
[36]. Similar studies of atypical adenomatous hyper-
plasia have shown telomerase expression in 27% of
AAH cases with low-grade dysplasia and as many as
75% of AAH with high-grade dysplasia. The expres-
sion of hTERT in BAC was observed in as many as
98% of cases, which indicates a clear role of telom-
erase in the development pathway from AAH to BAC.
Earlier studies had not shown the presence of telom-
erase in AAH [67].
p16
The loss of expression of protein p16, which is a spe-
cific inhibitor of cdk4/6, and, indirectly, also the
inhibitor of pRb phosphorylation, is often observed in
all types of carcinoma as well as in the states that pre-
cede them [1,6,12,23,40,58]. Jeanmart et al. [23]
report the loss of expression of p16 in 12% of squa-
mous metaplasia cases, 22% of low-grade dysplasia
cases, 14% of high-grade dysplasia cases and 47% of
the observed cases of CIS. The research conducted by
the same team later showed the loss of expression of
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p16 in 21% of hyperplastic epithelium, about 50% of
lesions ranging from squamous metaplasia to CIS
and increasing up to 63% in the cases of invasive
cancer [36] state that the loss of expression of p16
does not differ much as regards the frequency of
occurrence in AAH (20% of cases) and adenocarci-
noma (14.7% of cases), thus, it does not play a cru-
cial role in its development. The loss of expression
might result from the silencing of  p16INK4a gene
by means of metilation, which has been described by
many authors [35,49,66]. Numerous authors describ-
ing the expression of p16 in cytoplasm believe that it
is a non-specific reaction. As a result, such cases are
not taken into account. Recent studies of p16 protein
on the sub-cell level indicate that such an interpreta-
tion may be wrong. It has been proved that cytoplas-
mic activity of p16 may be the consequence of the
inactivation or mutation of protein, which results its
moving to cytoplasm (Fig. 4) [48]. The relationship
between the cytoplasmic localisation of p16 and the
highly malignant breast cancer phenotype seems to
confirm the above [16].
Cyclin D1
We often observe the over-expression of cyclin D1,
which while creating complexes with cyclin-depend-
ent  kinases 4/6 (cdk 4/6) leads to the pRb phosphory-
lation and the activation of the E2F transcription fac-
tor. The over-expression has an upward tendency and
is detectable in hyperplastic cells (9% of cases on aver-
age), metaplasia (6-11%), dysplasia of different grade
(17-67%) and CIS (33-53%) [23,36]. Also in AAH the
over-expression of cyclin D1 is high and ranges from
47 to 89% of cases depending on the degree of lesion
advancement (AAH with low-grade dysplasia - AAH
with high-grade dysplasia). However, a 28-60%
decrease in expression has been observed at an early
stage of adenocarcinoma development. Over-expres-
sion has been observed in 35% - 71% of the cases of
invasive adenocarcinoma [34,59]. It has not been
shown that the development of an invasive type of
both squamous carcinoma and adenocarcinoma is
related to the over-expression of cyclin D1, deranged
expression of proteins p53, p16, pRb, hTERT and pro-
liferation activity [23,34,36,47].
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Fig. 4. Immunohistochemical expression of P16; a. in cells representing AAH, b. adenocarcinoma, c. cytoplasmic staining in cells repre-
senting BCCD, d. bronchiolus with BCCD.
Ki-67
Proliferation index, as determined by a positive reac-
tion to Ki-67, is an important factor differentiating the
degrees of lesion development.  Ki-67 is a nuclear and
nucleolar protein, whose specific expression is
observed throughout the whole  cell cycle of prolifer-
ating cells, with the exception of G0  phase [17]. The
increase in the proliferation activity correlated to the
increasing degree of dysplasia and atypia, is a well-
known phenomenon described in the studies of the
epithelium of many organs [15,42,51,53]. Meert et al.
[39] showed that Ki-67 expression depends on the
degree of pre-cancer lesion development and increases
significantly from low-grade dysplasia to CIS.  A
comparison of the topography, the intensity of colour
reaction and the percentage of  Ki-67 positive cells,
indicates a significant difference between the stages of
low-grade - mild dysplasia (47-67%) and high-grade
dysplasia - CIS (91-100%). It clearly shows that pro-
liferation activity during the development of squamous
carcinoma is directly related to the increase of cell
atypia. Similarly, during the development of adenocar-
cinoma, proliferation index increases together with the
lesion development from AAH with low-grade and
high-grade dysplasia to bronchioloalveolar carcinoma
and invasive cancer [34].
Conclusion
Early diagnosis of pre-cancer lesions may be of cru-
cial significance to lowering lung cancer mortality.
Many molecular changes, which accompany the
multi-step process of the development of invasive
types of cancer, may be observed thanks to the appli-
cation of immunohistochemical markers (Table 1). It
must be noticed that the research concerning the
above mentioned proteins has not been conducted in
two lesions which are important for the development
of invasive types of cancer, i.e. Bronchiolar Colum-
nar Cell Dysplasia (BCCD) and bronchiolisation,
which could be a valuable source of information
about the potential pathways of development of inva-
sive lung cancer. A deeper knowledge of molecular
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Fig. 5. Immunohistochemical expression of P53; a. in cells representing AAH, b. adenocarcinoma, c. bronchiolization, d. BCCD.
and genetic changes accompanying pre-cancer states
may show new directions of early diagnostics of can-
cer development. 
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